8-K: UHS Reports Strong 2025 Growth, Forecasts 2026 Gains Amid Legal Win

Universal Health Services, Inc. announced robust financial results for 2025, including significant revenue and earnings growth, and provided an optimistic 2026 forecast, while also securing a new trial in a major lawsuit that had initially awarded $500 million in punitive damages.

Summary

• Universal Health Services, Inc. (UHS) reported a 9.1% increase in net revenues to $4.486 billion for Q4 2025, compared to $4.114 billion in Q4 2024.
• Net income attributable to UHS for Q4 2025 rose to $445.9 million, or $7.06 per diluted share, up from $332.4 million, or $4.96 per diluted share, in Q4 2024.
• For the full year 2025, net revenues increased by 9.7% to $17.365 billion, compared to $15.828 billion in 2024.
• Full year 2025 net income attributable to UHS was $1.489 billion, or $23.10 per diluted share, a significant increase from $1.142 billion, or $16.82 per diluted share, in 2024.
• Adjusted EBITDA net of noncontrolling interests (NCI) for Q4 2025 was $678.7 million, up from $614.6 million in Q4 2024, and for the full year 2025 was $2.590 billion, up from $2.246 billion in 2024.
• Net cash provided by operating activities decreased by $203 million to $1.864 billion for the full year 2025, primarily due to an unfavorable change of $385 million in accounts receivable.
• As of December 31, 2025, UHS had $889 million in available borrowing capacity under its $1.3 billion revolving credit facility.
• The Board of Directors authorized a $1.5 billion increase to the stock repurchase program in October 2025, leading to the repurchase of 4.650 million shares for approximately $899.3 million during 2025.
• A Nevada judge issued a verbal order on February 25, 2026, granting a new trial in the *St. Marys Medical Group* lawsuit based on juror misconduct, which is anticipated to vacate the prior verdict of approximately $4.7 million in compensatory damages and $500 million in punitive damages against UHS of Delaware, Inc.
• UHS recorded an $18 million legal reserve in Q3 2025 related to the Nevada lawsuit, noting that even if the verdict were reinstated on appeal, punitive damages would likely be reduced to a maximum of approximately $14 million under Nevada statutory law.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this filing very positively due to strong financial results, an optimistic 2026 forecast, and a highly favorable legal development that significantly reduces a major contingent liability.

Positives

• Net revenues increased by 9.1% in Q4 2025 and 9.7% for the full year 2025, demonstrating strong top-line growth.
• Net income attributable to UHS surged by 34.2% in Q4 2025 and 30.4% for the full year 2025, indicating robust profitability.
• Diluted EPS saw substantial growth, increasing by 42.3% in Q4 2025 and 37.3% for the full year 2025.
• Adjusted EBITDA net of NCI grew by 10.4% in Q4 2025 and 15.3% for the full year 2025, reflecting improved operational performance.
• A favorable verbal order from a judge granted a new trial in a lawsuit that had previously awarded $500 million in punitive damages against a subsidiary, significantly reducing potential financial exposure.
• The company recognized an after-tax unrealized gain of $71.5 million ($1.13 per diluted share) in Q4 2025 from its minority ownership in a healthcare generative artificial intelligence company.
• UHS repurchased 4.650 million shares for approximately $899.3 million during 2025, with an additional $1.425 billion available under the stock repurchase program, signaling confidence and returning value to shareholders.
• Acute Care Services on a same-facility basis saw net revenue increase by 6.9% in Q4 2025 and 8.5% for the full year 2025, with revenue per adjusted patient day increasing by 6.1% and 6.8% respectively.
• Behavioral Health Care Services on a same-facility basis experienced net revenue growth of 7.2% in Q4 2025 and 7.7% for the full year 2025, with revenue per adjusted patient day increasing by 5.6% and 6.8% respectively.

Negatives

• Net cash provided by operating activities decreased by $203 million to $1.864 billion for the full year 2025, primarily due to a $385 million unfavorable change in accounts receivable.
• The unfavorable change in accounts receivable was partly attributed to a $145 million increase in net receivables from Medicaid supplemental payment programs and a $50 million increase related to two recently opened hospitals.
• An unfavorable change of $67 million occurred in payments made in settlement of self-insurance claims, net of commercial insurance reimbursements.

Risks

• Payments from federal and state government programs (Medicare and Medicaid) are subject to statutory and regulatory changes, administrative rulings, interpretations, and funding restrictions, which could materially affect program payments and results of operations.
• Failure to renew supplemental Medicaid payment programs beyond their scheduled termination dates, or failure of public hospitals to provide necessary Inter-Governmental Transfers for state shares of Medicaid disproportionate share hospital programs, could cause actual results to differ materially from forecasts.
• Legislation adopted on July 4, 2025, attaching work and community service requirements to Medicaid eligibility, will likely limit Medicaid enrollment and expenditures, potentially reducing revenues and increasing uncompensated care.
• The same legislation places limits on provider fees used to increase federal Medicaid funding to states and eliminates certain exchange premium tax credits beyond 2025, which could further reduce revenues.
• Increased interest rates have significantly raised interest expense, reducing free cash flow, and future significant increases could unfavorably impact results of operations and access to capital markets.
• Changes in laws or policies governing foreign trade, including increased trade restrictions, tariffs, or taxes on imports, could impact competitive position, business operations, and financial results.
• The ultimate outcome of known and unknown litigation, including the Cumberland Hospital for Children and Adolescents matter and the Nevada lawsuit, is uncertain and could have a material adverse effect on the company, even with the recent favorable ruling.

Future Outlook

Universal Health Services, Inc. forecasts consolidated net revenues for 2026 to be between $18.417 billion and $18.789 billion, representing a 7.1% increase at the midpoint over 2025. Adjusted EBITDA net of NCI is projected to be between $2.641 billion and $2.789 billion, a 4.8% increase at the midpoint. Diluted EPS is forecasted to range from $22.64 to $24.52 per share, an 8.5% increase at the midpoint over 2025 Adjusted EPS. Capital expenditures are expected to be between $950 million and $1.1 billion.

Management Comments

• Our operating philosophy remains effective, enabling us to provide compassionate care to our patients and their loved ones.
• Our strategy involves building or acquiring high-quality hospitals in rapidly growing markets, investing in personnel and equipment for facility success, and becoming the leading healthcare provider in each community served.

Industry Context

StockSavvy.ai notes that Universal Health Services' strong financial performance in 2025, particularly the significant revenue and earnings growth across both acute care and behavioral health services, indicates resilience and effective strategy execution within a dynamic healthcare market. The company's investment in a healthcare generative AI company aligns with broader industry trends towards technological integration and efficiency improvements. The favorable legal outcome in the Nevada lawsuit provides a significant de-risking event, distinguishing UHS from peers potentially facing similar litigation challenges. The robust 2026 forecast suggests continued confidence in market positioning and operational capabilities, potentially outperforming segments of the industry grappling with persistent labor shortages and evolving reimbursement landscapes.

Legal Proceedings

• UHS of Delaware, Inc., a wholly-owned subsidiary, is a defendant in the lawsuit *St. Marys Medical Group, Inc. et. al. v. Pinnacle Medical Group, Northern Nevada, et. al.*, filed in Washoe County, Nevada.
• The lawsuit alleges intentional interference with contractual relationships and prospective economic advantage related to physicians joining Pinnacle Medical Group (50% owned by a UHS subsidiary) in 2021.
• A trial concluded on September 26, 2025, resulting in a verdict against UHS of Delaware, Inc. and other defendants for approximately $4.7 million in compensatory damages and $500 million in punitive damages against UHS of Delaware, Inc.
• On February 25, 2026, the judge issued a verbal order granting a new trial based upon juror misconduct, which is anticipated to vacate the entire verdict.
• Plaintiffs may appeal this ruling.
• Under Nevada statutory law, if the verdict were reinstated on appeal, punitive damages would be reduced to a maximum of approximately $14 million, with potential for further reduction by Nevada Supreme Court precedent.
• UHS recorded an $18 million legal reserve in Q3 2025 in connection with this matter.
• The ultimate financial exposure and outcome of this matter remain uncertain, and an adverse decision could have a material adverse effect on the company's financial condition.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, increased earnings per share, and the ongoing stock repurchase program, which signals management's confidence and returns capital.
• Employees (approximately 101,500) benefit from the company's continued growth and stability, as reflected in its strong financial results and strategic investments.
• Patients and their loved ones are impacted by the company's operating philosophy of providing compassionate care and its strategy of building or acquiring high-quality hospitals and investing in facilities.
• Government programs and taxpayers are affected by the company's reliance on Medicare and Medicaid revenues, as well as potential changes in legislation that could limit Medicaid enrollment and expenditures.
• Creditors and lenders are positively impacted by the company's strong financial health and liquidity, including $889 million in available borrowing capacity.

Next Steps

• A new trial will be scheduled at the court's convenience for the St. Marys Medical Group lawsuit.
• Plaintiffs may attempt to appeal the ruling granting a new trial.
• A conference call for investors and analysts will be held on February 26, 2026, at 9:00 a.m. eastern time to discuss the results and forecast.

Key Dates

Recommendation

The filing presents exceptionally strong financial results for 2025, with significant growth in revenue, net income, and EPS, coupled with an optimistic and robust forecast for 2026. The most impactful development is the favorable legal ruling granting a new trial, effectively vacating a $500 million punitive damages verdict, which substantially de-risks a major contingent liability. This combination of strong operational performance, positive future outlook, and a significant legal win makes Universal Health Services, Inc. a compelling 'strong buy' for a seasoned investor, indicating both fundamental strength and a reduction in a key overhang.

Keywords

Healthcare, Hospital services, Behavioral health, Acute care, Financial results, Earnings, Revenue growth, SEC filing, UHS, 2026 forecast, Litigation, Medicaid, Stock repurchase, EBITDA, EPS